Browsing by Author "Hochmair, Maximilian J."
Now showing items 1-3 of 3
-
Brigatinib Versus Crizotinib in Advanced ALK Inhibitor–Naive ALK-Positive Non–Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial
Camidge, D. Ross; Kim, Hye Ryun; Ahn, Myung-Ju; Yang, James C. H.; Han, Ji-Youn; Hochmair, Maximilian J.; Felip Font, Enriqueta (American Society of Clinical Oncology, 2020-11-01) -
Brigatinib Versus Crizotinib in ALK Inhibitor–Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial
Camidge, D. Ross; Kim, Hye Ryun; Ahn, Myung-Ju; Yang, James C. H.; Han, Ji-Youn; Hochmair, Maximilian J.; Felip Font, Enriqueta (Elsevier, 2021-12-01) -
Efficacy and Safety of Brigatinib Compared With Crizotinib in Asian vs. Non-Asian Patients With Locally Advanced or Metastatic ALK–Inhibitor-Naive ALK+ Non–Small Cell Lung Cancer: Final Results From the Phase III ALTA-1L Study
Ahn, Myung-Ju; Kim, Hye R.; Yang, James C. H.; Han, Ji-Yu; Li, Jacky Y.C.; Hochmair, Maximilian J.; Felip Font, Enriqueta (Elsevier, 2022-12)